Integrated Biopharma Terminates Agreement, Enters New Deal
Ticker: INBP · Form: 8-K · Filed: Apr 21, 2025 · CIK: 1016504
| Field | Detail |
|---|---|
| Company | Integrated Biopharma Inc (INBP) |
| Form Type | 8-K |
| Filed Date | Apr 21, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, agreement-termination
TL;DR
IBP terminated one deal, signed another, and took on new debt. Big moves happening.
AI Summary
Integrated Biopharma, Inc. announced on April 15, 2025, the termination of a material definitive agreement. The company also entered into a new material definitive agreement and incurred a direct financial obligation. The filing details these events under Items 1.01, 1.02, and 2.03 of the 8-K form.
Why It Matters
This filing indicates significant changes in Integrated Biopharma's contractual relationships, potentially impacting its financial obligations and strategic direction.
Risk Assessment
Risk Level: medium — The termination of a material agreement and the creation of new financial obligations suggest potential shifts in the company's operational or financial stability.
Key Players & Entities
- Integrated Biopharma, Inc. (company) — Registrant
- April 15, 2025 (date) — Date of earliest event reported
FAQ
What was the nature of the material definitive agreement that was terminated?
The filing does not specify the nature of the terminated material definitive agreement, only that it occurred on or before April 15, 2025.
What is the nature of the new material definitive agreement entered into by Integrated Biopharma?
The filing does not provide specific details about the new material definitive agreement, only that it was entered into on or before April 15, 2025.
What is the direct financial obligation incurred by Integrated Biopharma?
The filing indicates a direct financial obligation was created on or before April 15, 2025, but does not specify the amount or terms.
What is the significance of the 'Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant' item?
This item signifies that Integrated Biopharma has entered into a new financial commitment or arrangement that will appear on its balance sheet or affect its financial standing.
What were the previous names of Integrated Biopharma, Inc.?
Integrated Biopharma, Inc. was formerly known as Integrated Health Technologies Inc. (name change effective September 12, 2002) and Chem International Inc. (name change effective July 16, 1996).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 21, 2025 regarding INTEGRATED BIOPHARMA INC (INBP).